Observational studyEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2021
Characteristics and outcome of varicella-zoster virus central nervous system infections in adults.
Observational study in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Varicella zoster virus meningitis with a dermatomal rash in immunocompetent hosts: a systematic review and novel case report.Journal of neurovirology · 2026Pooled it
- Detection of sequelae from acute meningitis during clinical review by a healthcare provider: a systematic review and meta-analysis.BMC medicine · 2026Pooled it
- Development of a risk score to predict encephalitis by Herpes Simplex Virus and Varicella Zoster Virus.Journal of neurovirology · 2026Observational
- Article
- Prognostic Factors and Clinical Characteristics of Varicella Zoster Virus Meningitis: Impact of Treatment Delay and Age-Related Differences in a Japanese Tertiary Hospital.Neurology international · 2026Article
- Varicella-zoster virus-associated central nervous system infection in immunocompromised vs. immunocompetent herpes zoster patients: a comparative study.Frontiers in immunology · 2026Article
- Cerebral Hemorrhage in Varicella-Zoster Virus Encephalitis: A Case Study.The American journal of case reports · 2025Article
- Predictive value of blood routine-derived inflammation indexes for varicella-zoster virus meningitis in patients with acute herpes zoster.Frontiers in cellular and infection microbiology · 2025Article
- Article
- Article
- Encephalitis in HIV-negative immunodeficient patients: a prospective multicentre study, France, 2016 to 2019.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2024Article
- Can we forecast poor outcome in herpes simplex and varicella zoster encephalitis? A narrative review.Frontiers in neurology · 2023Review
- Comparisons in the changes of clinical characteristics and cerebrospinal fluid cytokine profiles between varicella-zoster virus meningitis/encephalitis and other central nervous system infections.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We conducted an observational retrospective study of all adults hospitalized for documented varicella-zoster virus (VZV) meningitis or encephalitis during years 2000-2015 in one referral centre. Thirty-six patients (21 males, 15 females) were included, with meningitis (n = 21), or meningoencephalitis (n = 15). Median age was 51 years [interquartile range, 35-76], and 6 patients (17%) were immunocompromised. Aciclovir was started in 32 patients (89%), with a median dose of 11 mg/kg/8 h [10-15]. No patient died, but 12 (33%) had neurological sequelae at discharge. Age was the only variable associated with adverse outcome (OR 1.98 [1.17-3.35] per 10-year increment, P = 0.011).
Indexed as
Identifiers
33907935What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.